AEROSEB-HC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AEROSEB-HC (AEROSEB-HC).
AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.
| Metabolism | Hydrocortisone is primarily hepatic via CYP3A4; iodoquinol is not extensively metabolized, with partial glucuronidation and enterohepatic circulation. |
| Excretion | Renal (primarily as metabolites; <5% unchanged); fecal (biliary excretion of metabolites). |
| Half-life | 1.5-2 hours (terminal) after intravenous administration; prolonged in hepatic impairment. |
| Protein binding | 90-95% (albumin and corticosteroid-binding globulin). |
| Volume of Distribution | 0.4-0.6 L/kg; indicates distribution into total body water and tissues. |
| Bioavailability | Oral: 80-90%; Intramuscular: 100%; Intravenous: 100%. |
| Onset of Action | Intravenous: 2-5 minutes; Intramuscular: 10-30 minutes; Oral: 30-60 minutes. |
| Duration of Action | Intravenous: 30-60 minutes; Intramuscular: 2-4 hours; Oral: 4-6 hours. |
| Molecular Weight | 362.46 |
AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.
| Dosage form | AEROSOL |
| Renal impairment | No adjustment required for topical application. Systemic absorption is minimal; however, in severe renal impairment (GFR <30 mL/min), use caution due to potential systemic corticosteroid effects. |
| Liver impairment | No specific adjustment for topical use. In Child-Pugh C cirrhosis, consider the risk of systemic corticosteroid accumulation; use with caution. |
| Pediatric use | Children >2 years: Apply a thin film to affected area twice daily for up to 7 days. Avoid prolonged use, occlusion, or application to large body surface areas. Safety in children <2 years not established. |
| Geriatric use | Elderly patients: Use the lowest effective duration and avoid prolonged use due to increased risk of skin atrophy and systemic absorption. Apply sparingly to limited areas. |
| 1st trimester | Limited data; avoid use due to potential teratogenicity from hydrocortisone. Use only if benefit outweighs risk. |
| 2nd trimester | Potential fetal effects from hydrocortisone; consider risk of fetal growth restriction. Use with caution. |
| 3rd trimester | Prolonged use may cause fetal adrenal suppression. Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for AEROSEB-HC (AEROSEB-HC).
| Placental transfer | Hydrocortisone crosses placenta; first-pass hepatic metabolism limits fetal exposure. Extensive systemic absorption from topical use may increase transfer. |
| Breastfeeding | Topical corticosteroids excreted in breast milk in small amounts; unlikely to cause adverse effects. Avoid application to nipples or large areas. Use shortest duration possible. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentUntreated bacterial, fungal, viral, or parasitic infectionsPerioral dermatitisAcne rosacea
| Precautions | Prolonged use may lead to systemic corticosteroid effects, including HPA axis suppression, Cushing's syndrome, and hyperglycemia., Risk of secondary infection due to immunosuppression., Local adverse reactions such as skin atrophy, striae, and perioral dermatitis., Avoid use in diaper area or under occlusive dressings. |
| Food/Dietary | No clinically significant food interactions are reported for topical hydrocortisone/pramoxine. No dietary restrictions necessary. |
Loading safety data…
| Lactation Rating |
| L2 (Probably Compatible) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adrenal suppression with prolonged use; avoid high doses and prolonged exposure. |
| Fetal Monitoring | Monitor for maternal adrenal suppression (HPA axis function) if high doses used. Fetal monitoring: ultrasound for growth restriction with repeated use. Newborn: observe for adrenal suppression if maternal high-dose use near term. |
| Fertility Effects | No known direct effects on fertility in humans. Animal studies show no impairment at therapeutic doses. |
| Clinical Pearls |
| AEROSEB-HC is a combination aerosol foam containing hydrocortisone acetate 1% and pramoxine hydrochloride 1% for topical use. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly in anogenital areas. The foam formulation enhances penetration and is less messy than ointments. Advise patients to avoid contact with eyes and mucous membranes. Use with caution in patients with skin infections or atrophy. Prolonged use in intertriginous areas may increase risk of local and systemic adverse effects. |
| Patient Advice | Apply a small amount to the affected area as directed, usually 2-4 times daily. · Do not cover the area with bandages or dressings unless instructed by your doctor. · Avoid use on broken skin, open wounds, or infected areas unless specifically prescribed. · Do not use for more than 2 weeks without medical supervision, especially in the anogenital region. · If symptoms do not improve or worsen, contact your healthcare provider. · Keep away from eyes, mouth, and other mucous membranes. · Wash hands after applying unless treating hands. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. |